Fiera Capital Corp Cuts Stock Holdings in argenx SE (NASDAQ:ARGX)

Fiera Capital Corp lowered its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 4.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 158,353 shares of the company's stock after selling 7,242 shares during the quarter. Fiera Capital Corp owned 0.26% of argenx worth $85,840,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ARGX. J.Safra Asset Management Corp grew its position in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after buying an additional 59 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after purchasing an additional 62 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after purchasing an additional 40 shares during the period. Cromwell Holdings LLC increased its holdings in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after buying an additional 66 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in argenx in the second quarter worth approximately $76,000. Institutional investors own 60.32% of the company's stock.

argenx Stock Up 0.8 %

Shares of ARGX traded up $4.56 during mid-day trading on Friday, reaching $596.00. The company had a trading volume of 180,505 shares, compared to its average volume of 307,843. The stock has a 50 day moving average of $545.48 and a two-hundred day moving average of $472.18. The stock has a market capitalization of $35.64 billion, a P/E ratio of -672.09 and a beta of 0.61. argenx SE has a 52-week low of $327.73 and a 52-week high of $611.22.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period in the previous year, the firm earned ($1.25) EPS. On average, sell-side analysts expect that argenx SE will post 2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ARGX. Barclays raised argenx from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co. increased their price target on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research report on Monday. Wells Fargo & Company lifted their price objective on shares of argenx from $547.00 to $639.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut shares of argenx from a "buy" rating to a "hold" rating in a research report on Friday, October 4th. Finally, Citigroup upped their price target on argenx from $512.00 to $635.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, argenx presently has an average rating of "Moderate Buy" and an average price target of $615.50.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.